Bleomycin Sulfate

目录号:S1214 别名: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。

规格 价格 库存 购买数量  
RMB 1410.29 现货
RMB 5474.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

质量管理及产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Bleomycin Sulfate是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。
体外研究

UT-SCC-12A和 UT-SCC-12B均对Bleomycin sulfate耐药,IC50分别为14.2 nM 和13 nM。[1]肺泡巨噬细胞与0.01 μg/mL到1μg /mL Bleomycin sulfate培养18小时显著比巨噬细胞单独培养分泌更多的成纤维细胞生长因子。Bleomycin sulfate刺激的巨噬细胞持续产生大量成纤维细胞生长因子,即使在移去Bleomycin sulfate,用新鲜培养基(不含Bleomycin sulfate)取代之后,该作用依然存在。Bleomycin sulfate刺激肺泡巨噬细胞导致的纤维素生长因子分泌被环己酰亚胺,和5-脂氧合酶抑制剂NDGA(去甲二氢愈创木酸)和BW755c抑制,表明其不仅需要蛋白质合成,也需要花生四烯酸代谢的5-脂氧合酶途径活性完全表达。[2] Bleomycin sulfate (400 µg/mL)培养24小时,降低NTera-2细胞的活性,增加caspase-3,-8和-9的活性,增加Bax和细胞质细胞色素C水平,并降低Bcl-2水平。[3]对于不稳定性畸变,Bleomycin sulfate对ADIPO-P2细胞的致染色体断裂作用在处理后至少持续10天。此外,暴露于Bleomycin sulfate的细胞处理10天后,端粒融合体的外观表明Bleomycin sulfate能够诱导延迟的端粒失稳。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NV;OUGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HaeFDjiJNzMECwJO69dQ>? MmnLNlQhcMLi NUT0bVJCcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MmTQNlYxQDh5MUG=
POLK WT NVnFVJNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHSU|RkUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> NWfNU2FxOjZyM{G0NFA>
POLK KO NEftdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\sdWlEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN NYTYSoNmOjZyM{G0NFA>
POLK CD NXyyNGtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfDTWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= M4np[FI3ODNzNECw
RLE/Abca3 NIfQdFVHfW6ldHnvckBCe3OjeR?= MlruNE41yqEQvF2= Moi3NVQ1yqCq M1PtRYlv\HWlZYOgZUBud3KyaH;sc4dq[2GuIHPoZY5o\SCocn;tJIVxcXSqZXzpZYwudGmtZTDtc5JxcG:ub3f5JJRwKGFid3nk[Uwhe3C{ZXHkMY92fCCvb4LwbI9td2e7wrC= MVSyOVc3ODV|OB?=
PMCs Mnm1SpVv[3Srb36gRZN{[Xl? NVztW3g2OC5z4pETNuKh|rypL33s NWH0dWNpOjUEoHi= MYjjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? MYGyOVU6PTZ2Mh?=
PMCs M1LSPWZ2dmO2aX;uJGF{e2G7 Mm\hNE4zyqEQvHevcYw> MUGyOQKBmzd{wrDo MULpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> NIPneYgzPTV7NU[0Ni=>
PMCs MW\GeY5kfGmxbjDBd5NigQ>? MVqwMlLDqM7:Zz;tcC=> MYG3NkBp NFHFRXJqdmS3Y3XzJIRm[3KnYYPld{BqdiCleYTvb4Vz[XSrbj24JIFv\CCHLXPh[IhmemmwIIDyc5RmcW5? M173b|I2PTl3NkSy
PMCs NU\OSohXTnWwY4Tpc44hSXO|YYm= Ml7uNE4zyqEQvHevcYw> MYWxNk8zPC92ODDo MmnlbY5kemWjc3XzJINmdGxibXnndoF1cW:w MX2yOVU6PTZ2Mh?=
IMR-32 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzPO{426ojUMUKwJOK2\y:vbB?= M1TiU|Ez6ojUNEigbC=> M{HpXGlEPTB;NkCgxtVoN22uIHH0JJRp\SCnbnSgc4YhOjRiaILzJI9nKGmwY4XiZZRqd25? NYDT[2JXOjV3M{[zOFU>
HT1080 M{nZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnYSZdzOSEQvF2= MkDoNlQhcMLi M1jk[4xm[WS|IITvJIEhTzJxTTDk[YxigQ>? M3jSdlI2PTF6OU[x
HT1080 M1roUWZ2dmO2aX;uJGF{e2G7 M2fieVEh|ryP NEPERXYzPCCqwrC= NGTBb3pqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl Ml23NlU2OTh7NkG=
HDFn MWLDfZRwfG:6aXPpeJkhSXO|YYm= NEL0[oo4OiCq M4e5d2lEPTB;OT6zNUXDqA>? NIntd3czPTJ5Nke5Ni=>
THP-1 NWTyT2w6S3m2b4TvfIlkcXS7IFHzd4F6 MUm3NkBp MmTITWM2OD12Lke3KS=> M4HYflI2Ojd4N{my
HT-29 MXnDfZRwfG:6aXPpeJkhSXO|YYm= NYrufFNNPzJiaB?= MWDJR|UxRTFzLkS5KS=> NUTFWnl5OjV{N{[3PVI>
HCT116  MlflR5l1d3SxeHnjbZR6KEG|c3H5 NX\SemdCPzJiaB?= M2HQeGlEPTB;MUGuN|Qm NHXTSY0zPTJ5Nke5Ni=>
A431 NXrCd3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nXUlUxNTJyMDDJWS=> MWW0PQKBkWh? MULpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M1vmUVI2OTBzMkm5
T24 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTfHp2PTBvMkCwJGlW NWHVPZVRPDkkgJno M{fq[olvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MWiyOVExOTJ7OR?=
AY-27  NF\o[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3VlUxNTJyMDDJWS=> MnzwOFjjiImq NG\B[oxqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MoPYNlUyODF{OUm=
A549 NV\pNpNyTnWwY4Tpc44hSXO|YYm= MkTLNUDDvWdxbV|CpC=> MWCwMVQ5KGh? MVLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MVSyOFk3OzZ|NR?=
MLE12 NIfNN29HfW6ldHnvckBCe3OjeR?= M1SwTlEhyrWpL33MxsA> MkfLNE01QCCq MXjpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NUPnSHEzOjR7NkO2N|U>
Jurkat M4nxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWeyNQKBkc7:bR?= M1W5blI16oDLaNMg M1vGboFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm NIrufJIzPDlzNki5Ny=>
HeLa  NEnsfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fPUWlEPTB;MUCuNuKh|ryP NVHyOpFJOjR5M{KzPVc>
C18-4 NGrs[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O2VlAuOTByIN88US=> M3H4R4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NY[3PG42OjR3N{G5PFI>
BMG-1  M1HTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWm0NE85OMLizsznM40> NXLrXJJuO8LiaB?= Ml\6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MYCyN|kxPjd{Nh?=
A459 M4\ZRWFxd3C2b4Ppd{BCe3OjeR?= MnyyNVAhdVV? MU[0PEBp MYHpcoR2[2W|IHHwc5B1d3Orcx?= M3zuNFI{QTB{N{[2
MOCK NI\EOHhCeG:ydH;zbZMhSXO|YYm= MUGxNEBuXQ>? M4LvcVQ5KGh? NEHQSFNqdmS3Y3XzJIFxd3C2b4Ppdy=> MnuzNlM6ODJ5Nk[=
MMP1 NWrzXW1bSXCxcITvd4l{KEG|c3H5 NIrPNXUyOCCvVR?= NH75VoQ1QCCq MmrpbY5lfWOnczDhdI9xfG:|aYO= MVSyN|kxOjd4Nh?=
A549 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn6VHkzODBizszN MVqyOEBpyqB? Mkex[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MXWyN|gxPTd7Mx?=
HCT-116 MoG3RZBweHSxc3nzJGF{e2G7 MkXIN{84NjVxMUWg{txoN22u NIO0eYY1QCCq NW\yZ4pjemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? Ml3NNlM4ODh4Nki=
HeLa Ml\CRZBweHSxc3nzJGF{e2G7 M3X1SlMwPy53L{G1JO69\y:vbB?= M4LiS|Q5KGh? M2fMTZJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> NVzRcmNMOjN5MEi2Olg>
HCT116 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\o[W0xNTFyMDFOwIcwdWx? M3Ty[FQ5KGh? NHfsRVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NYflWVdJOjN3MUiyNFE>
NCM460 NWnhS3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHWyem0xNTFyMDFOwIcwdWx? MX[0PEBp MkL4bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUHTV|dsOjN3MUiyNFE>
NT2  Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMNlQhcMLi NHfEUW1NTDVyPUSwNQKBkcL3Zz;tcC=> M1fpZVI{Ozh4NEKw
NT2  MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjFWppIPDhiaB?= MYPMSFUxRTFyMDFCuYcwdWx? NX\nSmxJOjN|OE[0NlA>
NT2  NX;nWXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW5UpY4OiCq MkLaUGQ2OD1{MPMAjeK2\y:vbB?= MXmyN|M5PjR{MB?=
NT2  NHTxcWNCeG:ydH;zbZMhSXO|YYm= MmGyOFAx6oDLwsXnM41t Mk\YNlQhcMLi NUfONVdocW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi NF;ZOlQzOzN6NkSyNC=>
NTera-2 NYnHeVVbTnWwY4Tpc44hSXO|YYm= NUHydZgxOTJyIN88[{9udA>? M1\XWVczKGh? NW\sUVJVe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> M3TOUFIzQDJ3M{W1
NCCIT NUj2W|J4TnWwY4Tpc44hSXO|YYm= M2rMc|EzOCEQvHevcYw> NX\3WYhDPzJiaB?= MlTBd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= NGPzeWgzOjh{NUO1OS=>
NTera-2 M17sS2Z2dmO2aX;uJGF{e2G7 Mm\sNVIxKM7:Zz;tcC=> NV;se2RDPzJiaB?= NYSxPFJFe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MU[yNlgzPTN3NR?=
NCCIT Mo\ESpVv[3Srb36gRZN{[Xl? NHPhR4MyOjBizsznM41t MXK3NkBp NULzZopKe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ M3\lSVIzQDJ3M{W1
NCCIT NFThfWJHfW6ldHnvckBCe3OjeR?= MmDvNVIxKM7:Zz;tcC=> MVi3NkBp NUnNTW83e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> NHXoUoIzOjh{NUO1OS=>
NTera-2 NUDJ[Y15TnWwY4Tpc44hSXO|YYm= NYfJc2RIOTJyIN88[{9udA>? NYDkOFJpPzJiaB?= NIjIZW1{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? MmK0NlI5OjV|NUW=
NCCIT MoS3SpVv[3Srb36gRZN{[Xl? MlfENVIxKM7:Zz;tcC=> NX60OmZYPzJiaB?= NFnYOop{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? MXyyNlgzPTN3NR?=
NTera-2 MWHGeY5kfGmxbjDBd5NigQ>? NVe4UY1XOTJyIN88[{9udA>? MkLMO|IhcA>? MnXwd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MkTINlI5OjV|NUW=
NCCIT NWr2fIljTnWwY4Tpc44hSXO|YYm= Mmn6NVIxKM7:Zz;tcC=> MYO3NkBp M{K0TpNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NFHVeWczOjh{NUO1OS=>
MDA-MB-468 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj1NQKBmzJyMNMg{txoN22O Mnv6NlQhcA>? NV\EV4hIcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NXfLblh{OjJ6MUmxPVY>
231-H2N MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrQVHZ[OOLCk{KwNOKh|rypL33M MV2yOEBp M1fXeolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NWf5b3J4OjJ6MUmxPVY>
A549  MVfGeY5kfGmxbjDBd5NigQ>? MX:yNFAwPDByIN88US=> NXfWV2dyemW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> MnfPNlI4PzN4OUe=
A549  NVO3U5pVTnWwY4Tpc44hSXO|YYm= NEWzW3kxNTRyMDFOwG0> NVe3[XhZOi12ODDo NFnzZYlk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl M1TRSFIzPzd|Nkm3
A549  M37iW2Z2dmO2aX;uJGF{e2G7 NVLiZotZOTByIN88UeKh NEj6XIMx6oDVNEigbC=> Mmn0Z4F2e2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NUm3NW1GOjJ5N{O2PVc>
A549  NITJOI9HfW6ldHnvckBCe3OjeR?= NH\RTGEyODBizszNxsA> NG[2RXkx6oDVNEigbC=> MVvjZZV{\XNiUFvENUBkdGWjdnHn[S=> NGTlTWwzOjd5M{[5Oy=>
A549  NYXBeo1WTnWwY4Tpc44hSXO|YYm= MnXKNVAxKM7:TdMg MXew5qCUPDhiaB?= NHrUWWhk[XW|ZYOgcYl1d2Oqb37kdolidCCub3PhcIl7[XSrb36gc4YhSmG6 M2LGVVIzPzd|Nkm3
A549  MXXGeY5kfGmxbjDBd5NigQ>? Mn\CNVAxKM7:TdMg NGXve4wx6oDVNEigbC=> NViyZm9b\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>? MViyNlc4OzZ7Nx?=
MCF-7/Her-18  MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfuUZlNOC52Mj2xO|AxKM7:Zz;tUC=> MoHENlQhcA>? MYXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M{nkTVIzPjJzNEC0
MCF-7 NH7jbY5RTFRxUFPJJHRz\WG2bXXueC=> NXP4R3I{OC5{NTFOwIcwdWxw MYOxMVQhcA>? MknUd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MmTBNlI2QTF{OES=
MDA-MB-231 MUHQSHQwWEOLIGTy[YF1dWWwdB?= NVG2WJFTOC5{NTFOwIcwdWxw NHO2RVMyNTRiaB?= Mor4d4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MYOyNlU6OTJ6NB?=
MDA-MB-235  M1j4[nBFXC:SQ1mgWJJm[XSvZX70 Mnv2NE4zPSEQvHevcYwv NWnKWYlQOS12IHi= MlLZd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> M2f0SlIzPTlzMki0
MCF-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMVIh|rypL33sMi=> Mn7nNlQwPDhiaB?= NVPkPGlxTUN3ME2xMlIh|rypL33M MXqyNlU6OTJ6NB?=
NCCIT  M4H5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGyNQKBmzF2MNMg{txoN22u MXS3NkBp NVLaVZdyVER3ME2xNlDDqM7:Zz;tcOKh MX:yNlU3OjF4MB?=
NCCIT  M4fieWZ2dmO2aX;uJGF{e2G7 Ml32O|IhcA>? NYHKb|NUe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> M{HBfFIzPTZ{MU[w
NCCIT  MnS2SpVv[3Srb36gRZN{[Xl? MYG3NkBp NUP2WXg1e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFkfGm4aYT5xsA> MUSyNlU3OjF4MB?=
NCCIT  NWH2c2NZTnWwY4Tpc44hSXO|YYm= M1XvPFczKGh? MX\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTliYXP0bZZqfHoEoB?= MmfoNlI2PjJzNkC=
NCCIT  NVPDUYJqTnWwY4Tpc44hSXO|YYm= NIPSUpo4OiCq MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NGnVbWgzOjV4MkG2NC=>
NCCIT  M4\KdmZ2dmO2aX;uJGF{e2G7 MWq3NkBp Mmjkd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NHHGSIozOjV4MkG2NC=>
NCCIT  NYDJS2dNTnWwY4Tpc44hSXO|YYm= MVG3NkBp MmXqd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt M1;xRVIzPTZ{MU[w
HeLa M1TuRmZ2dmO2aX;uJGF{e2G7 NUPZdI1FOzBxN{Cg{txoN22u M1[yfVI1yqCq NWrUZnA2cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? MVyyNlQ5Pzl|Nx?=
MCF-7  NUDJUVlmTnWwY4Tpc44hSXO|YYm= NFTxVW8{OC95MDFOwIcwdWx? NVe0S2FIOjUEoHi= NFL3PJVqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NU\leZBzOjJ2OEe5N|c>
HeLa NWjnXIx5S3m2b4TvfIlkcXS7IFHzd4F6 NYOxfY0zOzBxN{Cg{txoN22u NIflfHczPMLiaB?= NHPLN3dqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= MkK5NlI1QDd7M{e=
MCF-7  NF7pN3lEgXSxdH;4bYNqfHliQYPzZZk> MkLzN|AwPzBizsznM41t MUmyOOKhcA>? MkPLbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv MoSwNlI1QDd7M{e=
NT2 NIOw[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwWFExOC14MEFCpO69\y:vbB?= NWfUS21bOjRiaB?= M3\hOWlEPTB;NECwJOK2\y:vbB?= Moe1NlI1Pjl7NUK=
NT2 M1LhUmZ2dmO2aX;uJGF{e2G7 MnOwOFAxyqEQvHevcYw> NYXNWmM4OjRiaB?= MlnKd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh NIXmZpYzOjR4OUm1Ni=>
NT2 MWnGeY5kfGmxbjDBd5NigQ>? NYDVeIUyPDBywrFOwIcwdWx? NInmRoEzPCCq NIPYNFl{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= MVWyNlQ3QTl3Mh?=
NT2 NH3CRZBHfW6ldHnvckBCe3OjeR?= MmDIOFAxyqEQvHevcYw> NXH4c3AxOjRiaB?= NFqxeXN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> MnS1NlI1Pjl7NUK=
CHO NGnBbmxHfW6ldHnvckBCe3OjeR?= MVqyMlXDqM7:Zz;tcC=> NILSWYQyQCCqL{[g[C=> NUjqOGI2cW6mdXPld:KheGW{c3nzeIVv[2Vib3[gZ4hzd22xc3;t[UBl[W2jZ3W= NFOzeFkzOjJ|MEG5OS=>
Jurkat MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHtNE0yODEEoN88[{9udA>? NUexNmtoOjRiaB?= M2fCUoFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm Mo\pNlIzOjN|M{K=
Jurkat MmjXSpVv[3Srb36gRZN{[Xl? NYj5eIdrOzEEoN88[{9udA>? NF\1OJkzPCCq Mn36bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCleXPsbY5{KER|LDDBJIFv\CCEMR?= NIjqUpUzOjJ{M{OzNi=>
Jurkat Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIToTWExNTFyMNMg{txoN22u NUfROYVqOjRiaB?= MXjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? M3rIVlIzOjJ|M{Oy
Jurkat NWC4S3NCTnWwY4Tpc44hSXO|YYm= M2j5elMxyqEQvHevcYw> MYmyOEBp MXTpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? MlXLNlIzOjN|M{K=
U2OS EGFPnls MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCwMVLDqM7:Zz;tcC=> NGSwOoYzPCCq M{W5colvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NGDnboszOThzMUCwOy=>
U2OS KuEnls NILhSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMVLDqM7:Zz;tcC=> MkXKNlQhcA>? M{DiTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NEOzVGUzOThzMUCwOy=>
MCF-7 M2P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHoPYExNTRyMDFOwG0> NUjWb|ZnPzJiaB?= MVPMR|UxRTF3MT64xsDPxE1? NIP4NXQzOTdyM{K5NS=>
MCF-7/Adr  NYL6OYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LHOFAuPDByIN88US=> MV63NkBp MlLaUGM2OD13OD61xsDPxE4EoB?= MmT4NlE4ODN{OUG=
WI-38 NFvwXHdHfW6ldHnvckBCe3OjeR?= NGHMT44xNzRyL{iw5qCK|rypL33sxsA> MmjrN{Bp MUPpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MYiyNVU6QTZzMh?=
hBMSC NIj5NZFHfW6ldHnvckBCe3OjeR?= NF\ocVcxNzRyL{iw5qCK|rypL33sxsA> NInsTYs{KGh? M2XQOolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NYn4bIZDOjF3OUm2NVI>
NCI-H23 NHT1R2xHfW6ldHnvckBCe3OjeR?= M3zlb|AwPDBxOEFihKnPxGdxbX|CpC=> MYSzJIg> NEXZNWVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NYXnSVZwOjF3OUm2NVI>
A-549 MoXrSpVv[3Srb36gRZN{[Xl? MX:wM|QxNzhy4pEJ{txoN22uwrC= MoDqN{Bp NWPuc2ZRcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M2CyZ|IyPTl7NkGy
PBL  NHLYeJNHfW6ldHnvckBCe3OjeR?= NUP5SmNCOC92MD:4NQKBkc7:Zz;tcOKh NW\pV5FnOyCq NVGze29OcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NFrqU2EzOTV7OU[xNi=>
pol β −/− MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlI2NTJyMNMg{txoN22u M{LhOFI1yqCq MmPF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MYSyNVI2OTl2NB?=
pol β +/+ NIHWUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtNE4zPS1{MEFCpO69\y:vbB?= NHGzZoIzPMLiaB?= NYHuenBG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li M2jVS|IyOjVzOUS0
pol β −/− NWrMT29tTnWwY4Tpc44hSXO|YYm= M3[xd|AuOi53IN88[{9udA>? M37iZ|IhcA>? MoLuZ4F2e2W|IFTORUBl[W2jZ3W= NUTKdpo5OjF{NUG5OFQ>
pol β +/+ Mmf6SpVv[3Srb36gRZN{[Xl? M3LINlAuOi53IN88[{9udA>? MWWyJIg> MnXQZ4F2e2W|IFTORUBl[W2jZ3W= MkjDNlEzPTF7NES=
pol β −/− MUXGeY5kfGmxbjDBd5NigQ>? NYr6TIk6OC13IN88[{9udA>? NYnWRlBpPDhiaB?= NHHPZ|Nk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NHPKdlIzOTJ3MUm0OC=>
pol β +/+ Mm\xSpVv[3Srb36gRZN{[Xl? MofnNE02KM7:Zz;tcC=> NHjVbYw1QCCq NEXBR|Zk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> M3HWXFIyOjVzOUS0
TK6  M4L5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHCcpF4OjVvMUWwJO69\y:vbB?= NVKzZ3NVQTZiaB?= NG\nfWVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MViyNVA5OTR6Nx?=
TK6  sLUC+Apn1 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CSnUzPS1zNUCg{txoN22u MX65OkBp MV7pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MYKyNVA5OTR6Nx?=
TK6 sAPE1+Apn1 NH7MeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLINlUuOTVyIN88[{9udA>? NGjEemI6PiCq NXTLTnRYe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M1PqTVIyODhzNEi3
HCT116 NFHo[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqyOU0yPTBizsznM41t MoDlPVYhcA>? MmjjbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWSyNVA5OTR6Nx?=
HCT116 sLUC+Apn1 NHjINpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe0OHpLOjVvMUWwJO69\y:vbB?= NXfZVItzQTZiaB?= M3rRZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MlvkNlExQDF2OEe=
HCT116 sAPE1+Apn1 M4H2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHToVZYzPS1zNUCg{txoN22u NXnTN2hHQTZiaB?= NYnUcWdve2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MYGyNVA5OTR6Nx?=

... Click to View More Cell Line Experimental Data

体内研究 Bleomycin sulfate处理后第7天,NOX-/- 的BALf中CD45+细胞是WT的1.7倍多,其中57%为Mf,第21天,在WT中减少到67%,在NOX-/-中减少到83%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[4]
+ 展开
  • Cell lines: ADIPO-P2 细胞
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30分钟
  • Method: ADIPO-P2细胞在D-MEM高葡萄糖培养基中生长,用20%胎牛血清,青霉素(100 U/mL) 和链霉素 (100 μg/mL)增补,在37 °C 和5% CO2大气环境中培养。细胞在包含1.5×105 cells/mL的TC25 Corning培养瓶中单层培养。对于每个实验,建立两个培养瓶,一个用于对照组,一个用于处理培养。在对数生长期,ADIPO-P2细胞用2.5 μg/mL Bleomycin sulfate以30分钟脉冲处理。建立平行对照组,不暴露于Bleomycin sulfate。暴露时间和Bleomycin sulfate浓度根据先前实验室中进行的Bleomycin sulfate处理哺乳动物细胞的研究进行选择。Bleomycin sulfate脉冲处理结束时,细胞用Hank's平衡盐溶液清洗两次,并保存在新鲜培养基中直到采集。处理后5个传代培养期间,将细胞持续保持在培养基中。当培养基中融合(培养基中大约4×105 cells/mL)时,进行传代培养。为估计细胞生长,传代培养时,细胞通过胰蛋白酶化收集,每等份大约200 μL,用0.4%台盼蓝着色,测定活细胞数量。随后细胞悬浮在新鲜培养基中,重新分配到包含1×105 cells/mL的新培养瓶中继续生长。将剩余的细胞丢弃或置于另外的培养瓶中进行细胞遗传学分析,这在处理结束后18小时或第10天进行。为分析染色体突变,培养的最后3小时将colchicine (0.1 μg/mL)加入到细胞培养基。染色体的制备根据标准程序进行。采集后,将细胞低渗震动,固定在甲醇:乙酸(3:1)中,涂布在载玻片上,进行PNA-FISH。进行两个独立的实验。
    (Only for Reference)
动物实验:[7]
+ 展开
  • Animal Models: CD-1小鼠
  • Formulation: 生理盐水
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: 鞘内注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 1512.62
化学式

C55H85N17O25S4

CAS号 9041-93-4
稳定性 powder
in solvent
别名 NSC125066

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT03596918 Not yet recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles September 3 2018 Phase 1
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children''s Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01132807 Completed Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01026220 Completed Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Children''s Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3
NCT00983944 Withdrawn Lymphoma Ohio State University Comprehensive Cancer Center September 2009 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate价格 | Bleomycin Sulfate DMSO溶解度 | 采购Bleomycin Sulfate | Bleomycin Sulfate生产 | Bleomycin Sulfate 小鼠 | Bleomycin Sulfate化学结构 | Bleomycin Sulfate分子量 | Bleomycin Sulfate molecular weight | Bleomycin Sulfate说明书 | Bleomycin Sulfate供应商 | Bleomycin Sulfate体内 | Bleomycin Sulfate细胞系 | Bleomycin Sulfate浓度 | Bleomycin Sulfate nmr | Bleomycin Sulfate核磁 | Bleomycin Sulfate半数抑制浓度 | Bleomycin Sulfate体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID